« Projekte
An open-label randomized phase III study of intermittent oral Capecitabine in combination with intravenous Oxaliplatin (Q3W) ("XELOX") versus Fluorouacil/Leucovorin as adjuvant therapy for patients
Finanzierung:
Industrie;
Prof. Schmoll: An open-label randomized phase III study of intermittent oral Capecitabine in combination with intravenous Oxaliplatin (Q3W) ("XELOX") versus Fluorouacil/Leucovorin as adjuvant therapy for patients who have undergone surgery for colon carcinoma, UICC/AJCC stage III (Dukes stage C)
Kontakt

weitere Projekte

Die Daten werden geladen ...